PTG-200

Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug
Fierce Biotech
Tue, 05/30/17 - 06:20 pm
JNJ
Protagonist Therapeutics
M&A
Crohn's Disease
PTG-200